Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia-a pilot study (CROSBI ID 177857)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Pašalić, Daria ; Pauković, Paulina ; Cvijetić, Selma ; Pizent, Alica ; Jurasović, Jasna ; Milković-Kraus, Sanja ; Dodig, Slavica ; Muck- Šeler, Dorotea ; Mustapić, Maja ; Pivac, Nela ; Feher-Turković, Lana ; Pavlović, Mladen
engleski
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia-a pilot study
The aim of this study was to determine the relationship between BMI, biochemical parameters, and 5-HT genetic polymorphisms and prostate dysfunction in elderly general population. 117 elderly men subjects (60 men without symptoms of prostate hyperplasia, 42 men with untreated benign prostatic hyperplasia (BPH), and 15 men with prostate cancer (PCa) treated with finasteride or flutamide were included. Multiple comparisons showed significant difference in age, T-score, concentration of phosphorus, calcium, CRP, and PSA between the groups. T-score was the lowest and phosphorus concentration was the highest in the PCa group. Highest PSA, proteins, calcium, and Hekal’s formula score were found in the BPH group. Patients with PCa were more frequent GG+GA carriers of 5-HT1B 1997A/G gene polymorphism (p=0.035). Univariate regression analysis showed association of PCa-treated subjets with age (p=0.010) and 5-HT1B genetic polymorphism (p=0.018). Antiandrogen therapy affects T-score (p=0.017), serum phosphorus (p=0.008), glucose (p=0.036) and total proteins (p=0.050). Multivariate-stepwise logistic regression analysis showed the significant association of treated PCa with age (p=0.028) and inorganic phosphorus (p=0.005), and a marginal association with ultrasonographic T-score (p=0.052). Antiandrogen therapy might induce bone mineral loss in elderly PCa patients. Preliminary data imply that the genetic variants of 5-HT1B receptor might be associated with PCa.
prostate cancer ; antiandrogen therapy ; osteopenia ; genetic polymorphisms ; serotonine receptors ; aged general population
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
16 (6)
2012.
598-604
objavljeno
1945-0265
1945-0257
10.1089/gtmb.2011.0279
Povezanost rada
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita